32 results on '"Frouni, Imane"'
Search Results
2. Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain
3. Activation of mGlu2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism
4. [3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain
5. Metabotropic glutamate receptors in Parkinson's disease
6. Pharmacotherapy of Psychosis in Parkinson’s Disease
7. Cognition and serotonin in Parkinson's disease
8. Pharmacotherapy of Psychosis in Parkinson’s Disease
9. Pharmacokinetic profile of bitopertin, a selective GlyT1 inhibitor, in the rat
10. Anti-parkinsonian effect of the mGlu2 positive allosteric modulator LY-487,379 as monotherapy and adjunct to a low L-DOPA dose in the MPTP-lesioned marmoset
11. Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat
12. Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic
13. Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials
14. Autoradiographic labelling of 5-HT3 receptors in the hemi-parkinsonian rat brain
15. Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
16. Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease
17. Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
18. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat
19. Development and validation of a sensitive HPLC-HESI-MS/MS method for quantitative determination of bitopertin in rat and marmoset plasma
20. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset
21. Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat
22. Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset
23. Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates l-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset
24. Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
25. The highly selective mGlu 2 receptor positive allosteric modulator LY‐487,379 alleviates l ‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's disease
26. Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism
27. Highly sensitive HPLC-MS/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous dose
28. Classic animal models of Parkinson’s disease: a historical perspective
29. 5-HT2A blockade for dyskinesia and psychosis in Parkinson’s disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review
30. Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat
31. Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset
32. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.